{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:41:27Z","timestamp":1785526887537,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To examine voxel-wise associations between plasma phosphorylated tau biomarkers and cerebellum-normalised [^18F]fluorodeoxyglucose ([^18F]FDG) positron emission tomography (PET) uptake in cognitively impaired patients, and whether these associations persist in a cerebrospinal fluid (CSF)-confirmed Alzheimer\u2019s disease (AD) subgroup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      One hundred consecutive patients who underwent brain [^18F]FDG PET and plasma biomarker assessment within \u2264\u20096 months were included. Images were spatially normalised, smoothed, and divided voxel-wise by a subject-specific bilateral cerebellar reference value derived from Automated Anatomical Labelling 3 (AAL3) cerebellar regions. Voxel-wise multiple regressions tested associations with plasma A\u03b242\/A\u03b240, p-tau181, p-tau181\/A\u03b242, p-tau217, and p-tau217\/A\u03b242, adjusting for age and sex, in the full cohort and the CSF-confirmed AD subgroup (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200958).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the full cohort, plasma p-tau181 and p-tau181\/A\u03b242 showed negative associations with cerebellum-normalised [^18F]FDG uptake, predominantly in bilateral ventral temporal\/fusiform regions. The strongest and most spatially consistent finding involved p-tau181\/A\u03b242. Plasma A\u03b242\/A\u03b240 and p-tau217 showed no suprathreshold associations, whereas p-tau217\/A\u03b242 showed only a small focal cluster. In the CSF-confirmed AD subgroup, p-tau181\/A\u03b242 remained the most consistent tau-related marker, showing negative associations with cerebellum-normalised [^18F]FDG uptake in temporal\/temporo-limbic and posterior cortical regions, whereas p-tau217 and p-tau217\/A\u03b242 showed no suprathreshold clusters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>After voxel-wise cerebellar normalisation, plasma p-tau181\/A\u03b242 showed the most robust association with [^18F]FDG PET hypometabolism, predominantly involving bilateral ventral temporal\/fusiform regions in the full cohort and temporal\/temporo-limbic and posterior cortical regions in the CSF-confirmed AD subgroup. The heterogeneous full-cohort findings may partly reflect AD-versus-non-AD biological separation. Overall, plasma tau biomarkers and [^18F]FDG PET provide complementary molecular and metabolic information.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-07939-7","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T01:35:44Z","timestamp":1779845744000},"page":"5699-5708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma phosphorylated tau biomarkers map onto [^18F]FDG PET hypometabolism: a voxel-wise study in a clinical cohort with CSF-confirmed AD subgroup analysis"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8017-8858","authenticated-orcid":false,"given":"Agostino","family":"Chiaravalloti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Giuseppina","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Di Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Schillaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Martorana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"7939_CR1","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging. 2023;3:506\u201319. https:\/\/doi.org\/10.1038\/s43587-023-00403-3.","journal-title":"Nat Aging"},{"key":"7939_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, Salvad\u00f3 G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, et al. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA Neurol. 2023;80:360\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2022.5272.","journal-title":"JAMA Neurol"},{"key":"7939_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00259-023-06440-9","volume":"51","author":"HG Ryoo","year":"2024","unstructured":"Ryoo HG, Choi H, Shi K, Rominger A, Lee DY, Lee DS. Distinct subtypes of spatial brain metabolism patterns in Alzheimer\u2019s disease identified by deep learning-based FDG PET clusters. Eur J Nucl Med Mol Imaging. 2024;51:443\u201354. https:\/\/doi.org\/10.1007\/s00259-023-06440-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7939_CR4","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00259-018-4035-y","volume":"45","author":"PJ Nestor","year":"2018","unstructured":"Nestor PJ, Altomare D, Festari C, Drzezga A, Rivolta J, Walker Z, et al. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. Eur J Nucl Med Mol Imaging. 2018;45:1509\u201325. https:\/\/doi.org\/10.1007\/s00259-018-4035-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7939_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s13139-025-00932-2","volume":"59","author":"Y Bouter","year":"2025","unstructured":"Bouter Y, Glasnek RM, Wenzel JM, Bouter C. 18F-FDG-PET and Multimodal Biomarker Integration: A Powerful Tool for Alzheimer\u2019s Disease Diagnosis. Nucl Med Mol Imaging. 2025;59:453\u201371. https:\/\/doi.org\/10.1007\/s13139-025-00932-2.","journal-title":"Nucl Med Mol Imaging"},{"key":"7939_CR6","doi-asserted-by":"publisher","first-page":"e16255","DOI":"10.1111\/ene.16255","volume":"31","author":"KM Quispialaya","year":"2024","unstructured":"Quispialaya KM, Therriault J, Aliaga A, Tissot C, Servaes S, Rahmouni N, et al. Plasma phosphorylated tau181 outperforms [(18)F] fluorodeoxyglucose positron emission tomography in the identification of early Alzheimer disease. Eur J Neurol. 2024;31:e16255. https:\/\/doi.org\/10.1111\/ene.16255.","journal-title":"Eur J Neurol"},{"key":"7939_CR7","doi-asserted-by":"publisher","first-page":"e210211","DOI":"10.1212\/WNL.0000000000210211","volume":"104","author":"KM Quispialaya","year":"2025","unstructured":"Quispialaya KM, Therriault J, Aliaga A, Benedet AL, Ashton NJ, Karikari T, et al. Comparison of Plasma p-tau217 and [(18)F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia. Neurology. 2025;104:e210211. https:\/\/doi.org\/10.1212\/WNL.0000000000210211.","journal-title":"Neurology"},{"key":"7939_CR8","doi-asserted-by":"publisher","first-page":"e12490","DOI":"10.1002\/trc2.12490","volume":"10","author":"DC Matthews","year":"2024","unstructured":"Matthews DC, Kinney JW, Ritter A, Andrews RD, Toledano Strom EN, Lukic AS, et al. Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer\u2019s disease patients. Alzheimers Dement (N Y). 2024;10:e12490. https:\/\/doi.org\/10.1002\/trc2.12490.","journal-title":"Alzheimers Dement (N Y)"},{"key":"7939_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.brainres.2017.10.016","volume":"1678","author":"A Chiaravalloti","year":"2018","unstructured":"Chiaravalloti A, Barbagallo G, Ricci M, Martorana A, Ursini F, Sannino P, et al. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer\u2019s disease patients: A CSF and FDG PET study. Brain Res. 2018;1678:116\u201322. https:\/\/doi.org\/10.1016\/j.brainres.2017.10.016.","journal-title":"Brain Res"},{"key":"7939_CR10","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1007\/s10072-025-08250-3","volume":"46","author":"M Poli","year":"2025","unstructured":"Poli M, Bonomi CG, Tretola L, Rosa M, Di Donna MG, Moreschini A, et al. Beyond memory: leveraging CSF biomarkers in all MCI patients ahead of anti-amyloid therapies. Neurol Sci. 2025;46:4321\u20136. https:\/\/doi.org\/10.1007\/s10072-025-08250-3.","journal-title":"Neurol Sci"},{"key":"7939_CR11","unstructured":"The jamovi project. jamovi (Version 2.4) [Computer Software]. 2024."},{"key":"7939_CR12","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00259-021-05603-w","volume":"49","author":"E Guedj","year":"2022","unstructured":"Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B, et al. EANM procedure guidelines for brain PET imaging using [(18)F]FDG, version 3. Eur J Nucl Med Mol Imaging. 2022;49:632\u201351. https:\/\/doi.org\/10.1007\/s00259-021-05603-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7939_CR13","doi-asserted-by":"publisher","first-page":"109067","DOI":"10.1016\/j.neuropsychologia.2025.109067","volume":"207","author":"C Rorden","year":"2025","unstructured":"Rorden C. From MRIcro to MRIcron: The evolution of neuroimaging visualization tools. Neuropsychologia. 2025;207:109067. https:\/\/doi.org\/10.1016\/j.neuropsychologia.2025.109067.","journal-title":"Neuropsychologia"},{"key":"7939_CR14","doi-asserted-by":"publisher","first-page":"8193","DOI":"10.21105\/joss.08103","volume":"10","author":"TM Tierney","year":"2025","unstructured":"Tierney TM, Avila NL, Balbastre Y, Barnes G, Bezsudnova Y, Brudfors M, et al. SPM 25: open source neuroimaging analysis software. J Open Source Softw. 2025;10:8193. https:\/\/doi.org\/10.21105\/joss.08103.","journal-title":"J Open Source Softw"},{"key":"7939_CR15","unstructured":"The MathWorks, Inc. MATLAB, Version R. 2025. Natick, Massachusetts: The MathWorks, Inc. 2025."},{"key":"7939_CR16","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.3390\/app15105677","volume":"15","author":"C Motta","year":"2025","unstructured":"Motta C, Bonomi CG, Poli M, Mercuri NB, Martorana A, Chiaravalloti A. 18F-Fluorodeoxyglucose Uptake in Cerebrospinal Fluid Reflects Both Brain Glucose Demand and Impaired Blood\u2013Brain Barrier Transport in Alzheimer\u2019s Disease. Appl Sci. 2025;15:5677. https:\/\/doi.org\/10.3390\/app15105677.","journal-title":"Appl Sci"},{"key":"7939_CR17","doi-asserted-by":"publisher","first-page":"116189","DOI":"10.1016\/j.neuroimage.2019.116189","volume":"206","author":"ET Rolls","year":"2020","unstructured":"Rolls ET, Huang CC, Lin CP, Feng J, Joliot M. Automated anatomical labelling atlas 3. NeuroImage. 2020;206:116189. https:\/\/doi.org\/10.1016\/j.neuroimage.2019.116189.","journal-title":"NeuroImage"},{"key":"7939_CR18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimers Dement"},{"key":"7939_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"key":"7939_CR20","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3233\/JAD-2010-091504","volume":"20","author":"L Mosconi","year":"2010","unstructured":"Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ. Pre-clinical detection of Alzheimer\u2019s disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis. 2010;20:843\u201354. https:\/\/doi.org\/10.3233\/JAD-2010-091504.","journal-title":"J Alzheimers Dis"},{"key":"7939_CR21","doi-asserted-by":"publisher","first-page":"W76","DOI":"10.2214\/AJR.13.12363","volume":"204","author":"VK Shivamurthy","year":"2015","unstructured":"Shivamurthy VK, Tahari AK, Marcus C, Subramaniam RM. Brain FDG PET and the diagnosis of dementia. AJR Am J Roentgenol. 2015;204:W76\u201385. https:\/\/doi.org\/10.2214\/AJR.13.12363.","journal-title":"AJR Am J Roentgenol"},{"key":"7939_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41398-021-01709-9","volume":"11","author":"XN Shen","year":"2021","unstructured":"Shen XN, Huang YY, Chen SD, Guo Y, Tan L, Dong Q, et al. Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer\u2019s amyloid, tau and FDG PET status. Transl Psychiatry. 2021;11:585. https:\/\/doi.org\/10.1038\/s41398-021-01709-9.","journal-title":"Transl Psychiatry"},{"key":"7939_CR23","doi-asserted-by":"publisher","first-page":"e14609","DOI":"10.1002\/alz.14609","volume":"21","author":"F Anastasi","year":"2025","unstructured":"Anastasi F, Fern\u00e1ndez-Lebrero A, Ashton NJ, Ortiz-Romero P, Torres-Torronteras J, Gonz\u00e1lez-Escalante A, et al. A head-to-head comparison of plasma biomarkers to detect Alzheimer\u2019s disease in a memory clinic. Alzheimers Dement. 2025;21:e14609. https:\/\/doi.org\/10.1002\/alz.14609.","journal-title":"Alzheimers Dement"},{"key":"7939_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neurobiolaging.2021.07.005","volume":"107","author":"P Lemercier","year":"2021","unstructured":"Lemercier P, Vergallo A, Lista S, Zetterberg H, Blennow K, Potier MC, et al. Association of plasma A\u03b240\/A\u03b242 ratio and brain A\u03b2 accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer\u2019s disease. Neurobiol Aging. 2021;107:57\u201369. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2021.07.005.","journal-title":"Neurobiol Aging"},{"key":"7939_CR25","doi-asserted-by":"publisher","first-page":"e14357","DOI":"10.1111\/cns.14357","volume":"30","author":"X Xiong","year":"2024","unstructured":"Xiong X, He H, Ye Q, Qian S, Zhou S, Feng F, et al. Alzheimer\u2019s disease diagnostic accuracy by fluid and neuroimaging ATN framework. CNS Neurosci Ther. 2024;30:e14357. https:\/\/doi.org\/10.1111\/cns.14357.","journal-title":"CNS Neurosci Ther"},{"key":"7939_CR26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13195-025-01892-7","volume":"17","author":"FK Clemmensen","year":"2025","unstructured":"Clemmensen FK, Gramkow MH, Gonzalez-Ortiz F, Benedet AL, Tan K, Traichel W, et al. Prognostic value of plasma biomarkers in early Alzheimer\u2019s disease: a longitudinal clinical and neuroimaging study. Alzheimers Res Ther. 2025;17:243. https:\/\/doi.org\/10.1186\/s13195-025-01892-7.","journal-title":"Alzheimers Res Ther"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07939-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:04:47Z","timestamp":1785521087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07939-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7939"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07939-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Comitato Etico Territoriale Lazio Area 2 (Approval Code: 57.25CET2PTV; Approval Date: 27\/02\/2025).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The manuscript does not contain identifiable personal data or images.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}